Literature DB >> 3884019

Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis.

H J Williams, D E Furst, S L Dahl, V D Steen, C Marks, E J Alpert, A M Henderson, C O Samuelson, J N Dreyfus, A Weinstein.   

Abstract

A prospective, randomized, double-blind trial compared topical therapy with 0.85% normal saline, 2% dimethyl sulfoxide (DMSO), and 70% DMSO for treatment of digital ulcers in 84 patients with systemic sclerosis. There were no statistically significant differences among the 3 treatment groups in the improvement in the total number of open ulcers, total surface area of open ulcers, average surface area per open ulcer, number of infected ulcers, number of inflamed ulcers, or patient pain assessment. While some patients improved during the study, improvement could not be attributed to a specific treatment. Over one-quarter of the patients treated with 70% DMSO were withdrawn for significant skin toxicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884019     DOI: 10.1002/art.1780280311

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review.

Authors:  Paloma García de la Peña Lefebvre; María Betina Nishishinya; Claudia Alejandra Pereda; Estíbaliz Loza; Walter Alberto Sifuentes Giraldo; José Andrés Román Ivorra; Patricia Carreira; Iñigo Rúa-Figueroa; Jose María Pego-Reigosa; Santiago Muñoz-Fernández
Journal:  Rheumatol Int       Date:  2015-04-01       Impact factor: 2.631

2.  Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.

Authors:  Yann Savina; Thomas Duflot; Frederic Bounoure; Sylvain Kotzki; Pierre-Alain Thiebaut; Pierre-Alex Serreau; Mohamed Skiba; Jean-Michel Picquenot; Marie Cornic; Christophe Morisseau; Bruce Hammock; Laurent Imbert; Jean-Luc Cracowski; Vincent Richard; Matthieu Roustit; Jeremy Bellien
Journal:  Diab Vasc Dis Res       Date:  2019-07-03       Impact factor: 3.291

3.  Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.

Authors:  Robyn T Domsic; Shiyao Gao; Maureen Laffoon; Steven Wisniewski; Yuqing Zhang; Virginia Steen; Robert Lafyatis; Thomas A Medsger
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

4.  Adverse reactions of dimethyl sulfoxide in humans: a systematic review.

Authors:  Bennedikte Kollerup Madsen; Maria Hilscher; Dennis Zetner; Jacob Rosenberg
Journal:  F1000Res       Date:  2018-11-05

5.  Locoregional Treatments for Digital Ulcers in Systemic Sclerosis: A Systematic Review.

Authors:  Ingrid Costedoat; Maeva Masson; Thomas Barnetche; Pierre Duffau; Estibaliz Lazaro; Christophe Richez; Julien Seneschal; Marie-Elise Truchetet
Journal:  Acta Derm Venereol       Date:  2021-06-22       Impact factor: 3.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.